Mounting evidence is revealing a granularity within gene regulation that occurs at the level of mRNA translation. Within mammalian cells, canonical cap-dependent mRNA translation is dependent upon the interaction between the m 7 G cap-binding protein eukaryotic initiation factor 4E (eIF4E) and the scaffolding protein eukaryotic initiation factor 4G (eIF4G), the latter of which facilitates pre-translation initiation complex assembly, mRNA circularization, and 
Introduction
Emerging evidence suggests that regulatory control at the level of mRNA translation contributes significantly to gene expression and function (1) (2) (3) (4) . Consistent with this evidence, recent findings indicate that coordinated changes in post-transcriptional regulatory networks can alter cellular phenotype and behavior (2, 5) . A core cellular process underlying development, tumor metastasis, and tumor radiation and chemoresistance is epithelial to mesenchymal transition (EMT) (6, 7) . Since the metastasis and resistance to insult associated with cellular dedifferentiation are the foremost cause of cancer lethality (8, 9) , it is critical to develop a better understanding of the mechanisms by which EMT, and thus these two characteristics, are promoted. We previously defined a translational regulatory circuit driving EMT in vitro, and cancer progression in vivo, in breast epithelial cells (10) . The key regulator of this circuit is the cell marker E-cadherin (CDH1) concomitant with induction of expression of the mesenchymal cell markers Fibronectin (FN1) and Vimentin (VIM) (Supplementary Figure 1a) . Except for induction of phosphorylation of eIF4E at serine 209, which has been previously shown as required during TGF-β-induced EMT (20) , no change in steady state protein expression of any of the tested translation initiation factors was observed between the epithelial and mesenchymal states (Supplementary Figure 1a) . Co-immunoprecipitation experiments using extracts from TGF-β-induced cells revealed an association among CELF1, eIF4E, eIF4G1, eIF4B, eIF3H, CELF1 with the C-terminal, but not N-terminal, fragment of eIF4G1 was maintained.
Surprisingly however, the association between CELF1 and both eIF4E and PABP were preserved within this context (Figure 1e ), demonstrating that this tripartite interaction was independent of intact eIF4G1. EIF3C, eIF3H, and eIF4B retained their association with CELF1 upon 2A protease digestion, unless also digested with RNase A (Figure 1e ), indicating that these factors are a stable part of a remaining RNA-dependent complex that is not dependent on intact eIF4G1. We concluded that CELF1 is likely to bind eIF4E and PABP directly and that these associated proteins may be tethered to eIF4B and eIF3 in an RNA-dependent but eIF4G1-independent fashion.
While our experiments assessed CELF1's putative interactions with members of the canonical translation pre-initiation complex, these interactions were in the context of whole cell lysate. We thus next sought to determine whether these interactions were preserved at the mRNA m 7 G cap, using direct capture of eIF4E and its binding partners using extracts from TGF- protease also disrupted eIF4A's interaction with the m 7 G cap, but did not inhibit interaction of eIF4B, eIF3C, eIF3H, and PABP (Figure 1f) . However, the interaction between eIF4G1's Cterminus and CELF1 observed in whole cell lysate (Figure 1e ) was not recapitulated in the context of cap-analogue binding (Figure 1f ). This suggested that the CELF1/eIF4E/PABP interaction at the m 7 G cap of mRNA is likely to be independent of a direct association between CELF1 and eIF4G1.
To further test this model, we performed UV crosslinking/immunoprecipitation/qRT-PCR (RIP) assays from TGF-β-treated cells (Figure 1g) . Immunoprecipitation from cellular extracts derived from these cells with anti-CELF1 antibody revealed significant enrichment of GRE-containing (EGR3, FOSB, JUNB, and SNAI1) but not control (GAPDH and ACTB) mRNAs. As expected, immunoprecipitation with anti-eIF4E antibody resulted in significant enrichment for each of the mRNAs tested. In contrast, while immunoprecipitation with antieIF4G1 enriched each of the control mRNAs, this immunoprecipitation enriched only one GREcontaining mRNA (SNAI1). Similar results were obtained using tandem co-immunoprecipitation RIP assays in which anti-eIF4E immunoprecipitates were then immunoprecipitated once more with anti-CELF1 or anti-eIF4G1 (Figure 1h ).
CELF1 reduces the necessity for eIF4G1 in translation of GRE-containing EMT effector mRNAs
To directly assess the relationship between whether CELF1 and eIF4G in promoting the translation of GRE-containing mRNAs, we performed in vitro luciferase assays using translationally competent extracts derived from TGF-β-treated MCF10A cells that had been transiently transfected with control shRNA targeting β -galactosidase (GLB1 -negative control)
or CELF1. As expected, robust translation of a capped and polyadenylated Renilla luciferase reporter mRNA generated from the pRL-TK-CXCR4-6x reporter plasmid (CXCR4) within these extracts was significantly attenuated following cleavage of eIF4G1 by 2A protease (p<0.01; reporters irrespective of 2A protease digestion (again, contingent upon the presence of the GRE within these reporters) that was restored by addition of recombinant CELF1 protein (p<0.01 compared to CELF1 depleted extracts; Figure 2b ). This strongly suggests that the GRE within these reporters is repressive within the epithelial state unless directly bound by CELF1, and that binding of CELF1 to these elements promotes translation of GRE-containing mRNAs with a reduced requirement for intact eIF4G1. These results do not, however, rule out that the N-and C-terminal cleavage products of eIF4G1 may retain some function in promoting the translation of the GRE-containing reporters.
To directly address this caveat, we repeated the in vitro translation assay using extracts from which eIF4G1 had been immunodepleted (Supplementary Figure 2b) . As previously observed in the context of 2A protease digestion, immunodepletion of eIF4G1 had no effect on the translation of control reporters or reporters fused to GRE-containing CELF1 target UTRs (p>0.05), whereas translation of mutant UTRs lacking a GRE was significantly attenuated Our results are consistent with the notion that the GRE element inhibits translation of EMT effector mRNAs unless this element is bound by CELF1, which in turn reduces the dependency of translation of the GRE-containing mRNA on eIF4G1.
Phosphorylation of eIF4E is required for CELF1-driven EMT in MCF10A cells
We next examined the direct interactions taking place within the CELF1-containing translation pre-initiation complex more closely. It has been previously established that phosphorylation of eIF4E is required for TGF-β-induced EMT in MCF10A cells (20), and CELF1 expression promotes the translation of EMT effectors at the level of translational initiation (Figure 1a-d) . Given that our data suggests that CELF1 interacts with eIF4E at the m 7 G cap of GRE-containing mRNAs (Figure 1f) , we asked whether disruption of eIF4E phosphorylation would be sufficient to block CELF1-driven EMT in MCF10A cells. We employed a well-established system (20) in which MCF10A cells are stably transduced with either wild-type or S209A phosphor-null mutant murine Eif4e, followed by shRNA-mediated knock down of endogenous human EIF4E. While cells expressing a wild-type Eif4e transgene underwent EMT normally in response to CELF1 overexpression, CELF1-driven EMT was blocked by expression of the S209A mutant Eif4e (Figure 3a) . Reciprocal coimmunoprecipitation experiments demonstrated that CELF1 interacts with eIF4E, and that this interaction is strengthened by eIF4E phosphorylation (Figure 3b) . Indeed, translation of CELF1's previously defined EMT effector targets (10) was blocked in the S209A mutant expressing cells (Figure 3c-e) , consistent with the notion that eIF4E phosphorylation is required for CELF1's function as a promoter of mRNA translation and EMT driver.
CELF1 is an eIF4E-binding protein (4E-BP)
We next sought to further establish the direct interactions CELF1 might make within the translation pre-initiation complex. The YXXXXLφ motif (where X is any amino acid and φ is a hydrophobic amino acid residue) is common among eIF4G proteins and 4E-BPs, which utilize the motif to compete for binding to the tryptophan (W) 73 residue on the dorsal surface of eIF4E Figure 3f) . Figure 3g) (33). Immunoprecipitation of WT eIF4E or the W73A mutant eIF4E from MCF10A extracts revealed that CELF1's interaction with eIF4E was dependent upon the W73 residue (Figure 4d ). Our strategy of expressing the W73A mutant EIF4E in MCF10A cells precluded us from directly testing successful knockdown of the endogenous EIF4E. That we did not observe any interaction of endogenous CELF1 or ectopically overexpressed GFP-CELF1 with eIF4E in MCF10A cells expressing W73A mutant EIF4E confirmed successful knockdown of endogenous EIF4E in these cells. Again, these results were recapitulated using affinity-tagged purified proteins, indicating that the W73 mutation ablated the direct interaction between CELF1 and eIF4E in this latter context (Figure 4e ). Taken together with the above results, these data suggest that CELF1 is a novel mammalian 4E-BP that promotes translation of GRE-containing mRNAs in mesenchymal cells.
As stated above, given that canonical 4E-BPs block translation by competing with eIF4G1 for binding to eIF4E, it was counterintuitive that CELF1 would use a similar mechanism to promote translation. We thus sought to further investigate associations among the binding of eIF4E, CELF1, and eIF4G1 using affinity-purified proteins. Consistent with established literature and our own data described above, in vitro binding assays confirmed that eIF4G1 binds wild-type eIF4E, but neither the eIF4E W73A mutant (Supplementary Figure 4a) nor CELF1 (Figure 4f ). In addition, while purified CELF1 was able to stoichiometrically compete with purified eIF4G1 for eIF4E binding (and this competition was dependent upon CELF1 amino acids 365-371 - Figure 4g ), eIF4G1 was not conversely able to displace wild-type CELF1 protein bound to eIF4E (Figure 4h ). Additional in vitro binding experiments confirmed that CELF1 does not directly bind eIF4A (Supplementary Figure 4b) .
We next explored interactions among eIF4G1, CELF1, and PABP, again using affinitypurified proteins. As expected, in vitro binding confirmed interaction of PABP and eIF4G1, and consistent with our experiments performed using cell extracts, we found that CELF1 can also directly PABP (Supplementary Figure 5c) . Interestingly, competitive binding assays revealed that eIF4G1 did not displace CELF1 from PABP, but was instead able to bind the two complexed proteins (Supplementary Figure 4c) . These results indicate that CELF1 directly binds PABP and can thus in theory promote mRNA circularization of GRE-containing targets, but that it does this by binding a site on PABP distinct from the site bound by eIF4G1.
Interaction of CELF1 and eIF4E is required for CELF1-driven EMT in vitro and experimental metastasis in vivo
Given that we had previously demonstrated that overexpression of CELF1 is sufficient to induce EMT in several breast epithelial cell lines, we next set out to determine whether disruption of CELF1's interaction with eIF4E would abrogate this induction. EMT effector mRNAs, acting in cis on these mRNAs to promote non-canonical translation of these mRNAs via a direct interaction with eIF4E and PABP ( Figure 6 ).
Discussion
Our results identify a cap-dependent non-canonical translation initiation mechanism that facilitates EMT and metastatic progression by selectively promoting translation of GREcontaining EMT effector mRNAs. Even though the eIF4F complex has long been considered as core to canonical cap-dependent translation initiation (35), there is a developing paradigm that cap-dependent translation initiation independent of eIF4F may exist as a cellular mechanism for adaptive translation. This is especially true in the context of physiological or pathological conditions where canonical cap-dependent translation is broadly inhibited (36-40). However, to our knowledge a mechanism in which a 4E-BP directly associates with a cis-element in a mRNA's 3' UTR and is thus incorporated into a specialized complex to promote (rather than inhibit) the translation of the associated mRNA, has not been previously described. CELF1 itself has been previously implicated in regulation of the translation of the C/EBPβ transcription factor (41) and p21 protein (42) in hepatocytes and fibroblasts, respectively. However, the mechanism described for this regulation in these contexts is markedly different from the mechanism we have defined here. In both of these previous reports, CELF1 mediates regulation of translation by binding near the 5' region of the C/EBPβ and p21 coding sequences, and an interaction between CELF1 and the eIF2 initiation factor has been implicated in CELF1's regulation of C/EBPβ (43). In contrast, our data suggest that CELF1-mediated regulation of its targets in the context of EMT is via recruitment to GREs in the 3' UTR of affected transcripts, and we do not observe coimmunoprecipitation of CELF1 and eIF2 within our own experimental model system (data not shown).
In the scanning model of translation initiation, the decoding site and latch of the 40S subunit must open to allow the recruitment and migration of mRNA, and this unwinding process is catalyzed by the eIF4A helicase (11) . Surprisingly, our results support the conclusion that CELF1's role in promoting translation of GRE-containing EMT effector mRNAs is independent of an interaction with eIF4A. Much work has led to the now generally accepted notion that the 5'
UTRs of mRNAs encoding oncogenic factors are characterized by increased length and/or more complex structure, and thus that translation of these mRNAs is more dependent upon eIF4A
helicase activity than translation of mRNAs whose 5' UTRs are less structured (44-46). implied that eIF4A's cofactor eIF4B may function as an eIF4A-independent helicase for mRNAs with long structured 5' UTRs but weak dependence on eIF4G (49). Our demonstration here that CELF1 interacts with eIF4B may hint that a similar mechanism may be at play within our model system, but formal testing of this hypothesis, or identification of the helicase functioning within this context, is beyond the scope of the current study.
Perhaps even more surprising than the apparent absence of eIF4A in CELF1-dependent translation complexes is the finding that CELF1 can be classified as a 4E-BP that stimulates translation initiation. Virtually all 4E-BPs described to date bind eIF4E at W73 residue, thereby sterically occluding the eIF4E/eIF4G interaction, formation of the eIF4F translation pre-initiation complex, and bulk translation. Given this broadly conserved mechanism, our finding that CELF1, brought in cis by GRE-containing mRNAs, by definition occludes eIF4G by binding W73 yet concomitantly promotes translation of these mRNAs, is to our knowledge without precedent within a mammalian system. To our knowledge, the only other example of a 4E-BP able to coordinate translation initiation is Mextli, a gene product identified in Drosophila that promotes germ stem cell maintenance (50) . Nonetheless, it is intuitively clear that additional regulatory mechanisms are likely to dictate CELF1's recruitment to the translation pre-initiation complex and its activity within that complex, and that unraveling these mechanisms is an exciting arena for future study.
The bulk of our functional data might be interpreted to suggest that CELF1-mediated translation of GRE-containing EMT effector mRNAs is independent of eIF4G1. However, it should be noted our methodology does not entirely rule out a role for eIF4G1 given that residual protein remains after immunodepletion and perhaps even after cleavage with 2A protease.
Indeed, the global function of the core translation machinery has been consistently shown to be surprisingly refractive to depletion of central components of this machinery (32,36-40,51).
Additionally, our data does not formally rule out that eIF4G1 is incorporated into CELF1-conatining translation initiation complexes in a non-canonical fashion. Significant additional work is required to fully characterize the components of the CELF1-specific translation initiation complex within this context and determine precisely how the 43S pre-initiation complex is recruited to these mRNAs. In addition, given that our results demonstrate an RNA-independent interaction with eIF4E and PABP, both of the latter of which are thought to bind virtually all mRNAs, it is patently clear that additional mechanisms dictating the specific incorporation of CELF1 into translation pre-initiation complexes of GRE-containing mRNAs remain to be discovered. Further, that GREs within the mRNAs that we have examined here confer repression in the epithelial state, where CELF1 protein is not present, suggests the existence of a second trans-regulator that must be evicted by CELF1 to allow translation activation and then EMT to occur. This is an exciting arena for future study.
While the components, mechanisms, and underlying signaling pathways dictating canonical translation pre-initiation complex formation in mRNA translation are well-established, the contribution of non-canonical complexes to translation is only beginning to be revealed.
Already however, it is clear that regulation of translation is both context-and cell-type dependent in terms of target specificity and activity (39,40,47,52). In theory, encoding more than one mechanism of cap-dependent translation initiation allows cells additional control over protein synthesis, perhaps where additional granularity in this control might provide the cell an adaptive advantage in response to a specific physiological stimulus or genetic insult. It is thus tempting to speculate that additional specialized translational complexes remain to be discovered, both in normal cellular function and within the diseased or transformed state. From the latter perspective, a more robust mechanistic understanding of analogous specialized mechanisms of translation may reveal novel vulnerabilities that may be exploited in the clinic, especially given the initial promise within clinical trials of drugs targeting canonical translation initiation as a bulk process (53,54),
Materials and Methods

Cell culture and treatment
The MCF10A cell line was obtained from the ATCC (Manassas, VA) and cultured as described previously (10 
Cell lysis, immunoblot, and immunoprecipitation
Cell lysis and immunoblotting was performed as described previously (10, 55) . Supplementary Table 1 provides the list and associated information of antibodies used in the current study. All blots were also probed with GAPDH to confirm equal loading. 
RNA immunoprecipitation (RIP) and data analyses
RIP and data analyses was performed as described previously using primers described in
Supplementary Table 2 (10).
Polysome profiling, and quantitative real time PCR (qRT-PCR)
Polysome profiling from MCF10A cells stably expressing either wild-type or S209A mutant eIF4E and transiently transfected with CELF1 expression plasmid (20) was performed using 10-50% sucrose gradients as described previously (10) . Thirty OD units per condition were used for polysome profiling. We used TRIzol LS reagent (ThermoFisher Scientific) to extract RNA from equal volumes of the various polysome fraction and total lysate aliquots as described before (10).
RNAs isolated from equal volume of polysome fractions or input total lysate were primed with random hexamers and reverse transcribed using SuperScript III Reverse Transcriptase 
Plasmid constructs
The pEGFP-N1-CELF1 putative eIF4E binding mutants were generated via site-directed mutagenesis using the QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, La Jolla, CA) and primers listed in Supplementary (wild-type and W73A mutant) cloned into the pGEX-5X-1 vector were kind gifts from Dr. YanHwa Wu Lee (58) and were used to generate the phosphomimic wild-type and W73A mutant GST-EIF4E by site directed mutagenesis using primers listed in Supplementary Table 2 . The wild-type and W73A EIF4E coding sequence entry constructs for overexpression were generated from FLAG-EIF4E, and FLAG-EIF4E (W73A) plasmids gifted by Dr. Katherine L Borden (59).
Expression constructs for wild-type and W73A mutant EIF4E were generated by Gateway Cloning (ThermoFisher Scientific) into the pLenti6.3 vector. ShRNA plasmid constructs targeting the 3' UTR of EIF4E were cloned into the pGIPZ backbone using oligonucleotides listed in Supplementary Table 2 .
Transfection and transduction
Transient transfection was performed using Lipofectamine LTX (Life Technologies, Carlsbad, CA), per the manufacturer's instructions. The pGIPZ lentiviral particles were generated by transfection of 293Ts using Lipofectamine 2000 (ThermoFisher Scientific), per the manufacturer's instructions. The pLenti6.3 lentiviral particles were generated by transfection of 293Ts as described previously (60) . For transduction, early passage cells were seeded at 500,000 cells per 10-cm 2 dish one day prior to infection and transduction was performed as described previously (61 
Surface sensing of translation (SuNSET)
SuNSET technique was performed as described previously (33). Briefly, indicated cells were labeled for 10 minutes using puromycin (10 µg/ml). Cells were harvested, lysed as described above, and resolved using SDS-PAGE. Blots were probed with anti-Puromycin antibody (Kerafast, Boston, MA) and subsequently stained with Coomassie Blue R250 (Sigma-Aldrich).
Recombinant protein expression and purification
The pGEX-5X-1 WT/S290D and W73A/S209D EIF4E constructs were transformed into competent BL21(DE3) E. coli (ThermoFisher). One colony was picked the following day, Following growth, cells were harvested and pelleted (5000 g, 10 minutes). The cell pellet was resuspended in 50 ml lysis buffer (50 mM PBS, pH7.6, 500 nM NaCl, 1 nM EDTA, and 1 mM PMSF) and disrupted by passing through microfluidizer. Lysate was clarified by centrifugation at 50,000 g for 30 minutes at 4 0 C. Clarified lysate was passed through a 022 µM syringe filter and loaded onto 1 ml GE GSTrap 4B column (GE AKTA) at 0.5 ml/minute. The column was washed with 20 column volumes of lysis buffer before elution using freshly prepared lysis buffer containing 20 mM glutathione at 0.5 ml/minute. The expression plasmids for the 6xHis-tagged CELF1 proteins were transformed, cultured, and induced similarly as above. The His SpinTrap Kit (GE Healthcare) was used according to manufacturer's recommendations to purify the recombinant CELF1 proteins. Finally, buffer exchange was performed using 5 ml desalting spincolumns (MilliporeSigma, Burlington, MA). Desalted and purified protein samples were aliquoted, glycerol was added at 10% (v/v), snap frozen, and stored at -80 0 C until further use. The C-MYC/DDK tagged purified recombinant human EIF4G1, EIF4A1, and PABP proteins were purchased from OriGene (Rockville, MD).
In vitro binding assays
Recombinant, bait GST-tagged EIF4E or 6xHis-tagged CELF1 proteins (1 μ M) were initially bound to glutathione-agarose beads (ThermoFisher Scientific) or Ni 2+ beads (GE Healthcare), respectively. Post-binding, beads were washed three times with wash buffer containing 50 mM
Tris-HCl (pH 7.4) and 20% glycerol before addition of prey proteins (0.1 -10 μ M). Mixtures were incubated at room temperature with rocking for 2 hours. Beads were washed three times with wash buffer containing 500 mM NaCl. The protein bound to the beads were resolved by SDS-PAGE and analyzed by both Coomassie staining and immunoblot analysis.
Mammalian cell free in vitro translation
Wild-type or GRE deletion mutant CRLF1 and SNAI1 3' UTRs, two of the GRE-containing mRNAs, were fused downstream of the Renilla luciferase coding sequence in the broadly used pRL-TK CXCR4 6x reporter plasmid (Addgene, Cambridge, MA) as described before (10) . T7
forward and respective 3' UTR-specific reverse primers, listed in Table S2 , were used to generate PCR templates for in vitro transcription from pRL-TK CXCR4 6x, pRL-TK CRLF1,
pRL-TK CRLF1
Δ GRE, pRL-TK SNAI1, and pRL-TK SNAI1 Δ GRE plasmids. Capped and polyadenylated mRNA templates were generated using the mMESSAGE mMACHINE kit and
Poly(A) Tailing kit, respectively (ThermoFisher Scientific). For cap-independent translation experiments, PCR templates were generated to amplify the EMCV IRES or HCV IRES driven
Renilla luciferase from the pFR_EMCV (10) and pFR_HCV_xb plasmid (Addgene), respectively, using primers listed in Supplementary Table 2 . These amplicons were then used to generate the poly-adenylated mRNA template as above, except without addition of the cap analogue.
MCF10A cells were transiently transfected with shRNA targeting either GLB1 or CELF1 as described previously (10) , and subsequently treated with TGF-beta for 72 hours. Cell-free extracts from these cells were prepared and in vitro translation was performed as described previously (62) . Briefly, cells were lysed in freshly prepared ice-cold hypotonic lysis buffer (10 mM HEPES, pH 7.6, 10 mM potassium acetate, 0.5 mM magnesium acetate, 5 mM DTT, EDTA-free protease and phosphatase inhibitor cocktail (ThermoFisher Scientific). Where indicated extracts were treated with 4 ng/µl recombinant coxsackievirus B3 2A protease as described above. For immunodepletion of eIF4G1, extracts were processed as described above for immunoprecipitation with an anti-eIF4G1 antibody or beads alone (Supplementary Table 2) and the process was repeated twice.
In vitro translation reactions were set up in a total reaction volume of 10 µl per sample Translation read-out was performed using the dual-luciferase reporter assay system (Promega) as per the manufacturer's protocol on a Tecan M200 multimode reader running Tecan Magellan software (Tecan). Data is presented as mean ± standard deviation (SD) of luciferase light units.
In vitro migration and invasion assay
In vitro migration and invasion assays were performed using Culturex 96 Well Cell Migration and Invasion Assay kits (Trevigen, Gaithersburg, MD) as described before (10) . Data obtained were used to analyze percent migration and invasion and were expressed as percent mean ± standard deviation.
Animal studies
All mouse procedures were approved by the Institutional Animal Care and Use Committees of the Baylor College of Medicine and were performed as described before (10 
Statistical analysis
Laboratory data are presented as mean ± standard error of mean (SEM) unless otherwise stated.
When two groups were compared, the Student's t test was used unless otherwise indicated and a pval < 0.05 was considered significant. with affinity-purified phosphomimic (GST-eIF4E-S209D) or mutant (GST-S209D/W73A) eIF4E.
(f) Purified 6xHis-CELF1 or GST-eIF4E-S209D was mixed with purified DDK-eIF4G1.
Complexes were pulled down with Ni 2+ or purified GST beads, respectively, and immunoblotted Canonical Model CELF1 Targets in EMT and Cancer Progression ?
